| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d4756ad6246c689691888aaa93be2cda
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1cded1dd9dcc9dac6c1d9e44d8c1f78f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8c8baa2365feae914fa04eaf9ab7dfc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1305aacb893c7b38ee80834ad2ce98c1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e74062cc932b7c721f3f89ce307fba34 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S436-824 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-3274
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-3212
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-286
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01D15-3809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-543 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-543 |
| filingDate |
2005-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef8fd1d4eeaddd83e5ac0a41fb832f10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f22cd5292eece29feb20724de4fdc09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c07b14153e071d9ebcc837f8ef9bf6cb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f039bb3c7a9469f4f2711459ec41da22 |
| publicationDate |
2014-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8728828-B2 |
| titleOfInvention |
Purification of immunoglobulins |
| abstract |
The present invention relates to a separation matrix comprised of porous particles to which antibody-binding protein ligands have been immobilized, wherein the ligand density is in the range of 5.0-10 mg/ml; the gel phase distribution coefficient of the particles expressed as K av for a dextran of size 110 kDa is above 0.65 and the median particle diameter is between 65-84 μm. The carbohydrate material is preferably highly cross-linked agarose. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10525376-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11517879-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10526367-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10918971-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017137461-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013090259-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017021286-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11353468-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10875007-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9534023-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9534246-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11155575-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10343142-B2 |
| priorityDate |
2004-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |